Genitourinary Cancers

Approximately 4 years after the FDA approval of 2 powerful new oral androgen-targeting agents for metastatic castration-resistant prostate cancer, an analysis raised issues complicating treatment with the 2 drugs, as well as what oncologists do not yet know.

Mayer Fishman, MD, PhD, medical oncologist, Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center, professor, Department of Oncologic Sciences and of Internal Medicine, University of South Florida Morsani College of Medicine, discusses the available agents to treat patients with renal cell carcinoma.

As a group, Rio Grande Urology shares a sense of obligation and culture. Its leaders have embraced an integrative model approach and sees the advantages of it.

Patients with renal cancer who underwent cytoreductive nephrectomy and targeted therapy had improved survival compared with patients who did not undergo the surgery.

Gary D. Steinberg, MD, discusses the impact of atezolizumab (Tecentriq) on the treatment landscape of bladder cancer, the resistance to finding effective therapies for the disease, and what potential role immunotherapy may have in the field going forward.

Randy F. Sweis, MD, covers the immunotherapy advancements in prostate cancer, renal cell carcinoma, and bladder cancer, and what refinement lies ahead in each of these areas.

The lack of cooperation and inability to compromise, at the expense of our country’s best interests, has resulted in gridlock.

Maha H. Hussain, MB ChB, whose work has helped advance treatment and care of men with prostate cancer, was honored in the Genitourinary Cancer category with a 2015 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to recognize leaders in the field.

Alexander I. Sankin, MD, discusses how bladder cancer researchers are looking beyond PD-L1 and CTLA-4 to HHLA2, a potentially druggable new checkpoint target.

Michael Fabrizio, MD, and Dana Adams, COO, provide their perspective on the challenges that urology practices face today.

Cabozantinib (Cabometyx) has received a positive recommendation from the EMA's Committee for Medicinal Products for Human Use for use as treatment for patients with advanced renal cell carcinoma after the failure of VEGF-targeted therapy.

The CHMP has recommended the approval of lenvatinib in combination with everolimus for patients with advanced renal cell carcinoma following one prior VEGF-targeted therapy.

Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discusses the overall significance of a study examining an elevated preoperative classical monocyte PD-1 mean fluorescence intensity level in patients with clear cell renal cell carcinoma.

Saeed Rafii, MD, PhD, MRCP, discusses the PD-L1 inhibitor durvalumab, the encouraging findings of it in Study 1108, and the evolving landscape of bladder cancer.

Sumanta Kumar Pal, MD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses biomarker development in the field of renal cell carcinoma (RCC).

Peter O'Donnell, MD, discusses the encouraging IMvigor 210 results, the impact of atezolizumab (Tecentriq) in the treatment landscape, and the role of immunotherapy in metastatic urothelial carcinoma.